Experiencing daytime sleepiness is something that is usually perceived as a minor inconvenience, but for older adults, it could be an early warning sign of Dementia. This neurodegenerative disease leads to the progressive decline of brain cells. This eventually

affects memory, cognition, and personality, making everyday tasks more difficult. As one of the fastest-growing neurological disorders across the world, dementia poses a significant health threat to ageing populations.

Is Dementia Linked To Poor Sleep?

For this study, researchers followed 445 older adults (average age 76) over three years, aiming to determine whether poor sleep could increase the risk of mild cognitive impairment (MCI), which often leads to dementia. At the start, none of the participants had MCI, but by the end of the study, 36 individuals had developed the condition.

The researchers discovered that participants with poor sleep were more likely to develop MCI compared to those who slept well. However, when depression symptoms were taken into account, the link between poor sleep and MCI became less pronounced, suggesting that while sleep issues are a concern, mental health also plays a key role in dementia risk.

To assess sleep quality, the Pittsburgh Sleep Quality Index (PSQI) was used, evaluating factors such as sleep duration, disturbances, and daytime alertness. Among these, "daytime dysfunction"—defined as excessive sleepiness and low energy during the day—was most strongly associated with an increased risk of MCI. Those experiencing daytime dysfunction were more than three times as likely to develop MCI as those who didn’t report such symptoms.

There are many types of dementia:

Dementia is not a specific disease. According to the Centers for Disease Control and Prevention (CDC), it is an overall term that describes a decline in mental ability that interferes with daily life. People with dementia often have symptoms like trouble remembering, thinking, or making everyday decisions. These symptoms tend to get worse over time.

Alzheimer’s disease is the most common type of dementia, and it mostly affects the elderly. Each form of dementia has a different cause. Though dementia mostly affects older adults, it is not a part of normal ageing. An estimated 6.7 million older adults have Alzheimer's disease in the United States. That number is expected to double by 2060, as per data from the CDC.

In 2022, 3.8% of men and 4.2% women in US were diagnosed with dementia. The percentage of people increase with age from 1.7% for those aged 65-74 to 13.1% for those aged 85 and older. Alzheimer's accounts for 60 to 80% of all dementia cases and it is most prevalent in California, Florida, and Texas, as these states have the highest number of people.

Panic has gripped the residents of two villages in Rajasthan's Salumbar district, where five children have reportedly died within five days. The reason: an unknown disease characterized by a sudden onset of fever that worsens rapidly, and claims the lives of children within 24 hours.

According to officials, the children who died were between 2 and 4 years old, and all of them developed high fever, convulsions, and vomiting before their condition worsened rapidly.

Besides the five children who died, another 8 children are reportedly showing similar symptoms of the unknown disease.

The incident has been reported from Ghata and Lalpura villages in Lasadiya block.

The Disease Yet To Be Identified

The deaths have created fear among villagers, who submitted a memorandum to the SDM and health officials, seeking immediate action and identification of the disease.

District officials, along with a medical team, have reached the villages. The District Collector has ordered an inquiry. Medical teams are currently stationed in the villages, according to local media reports. Blood samples and other tests are being conducted to check for viral infection, brain fever, or any seasonal illness.

After preliminary treatment, five of the eight children newly affected with the mystery illness were referred from Lasadiya CHC to Udaipur District Hospital. Meanwhile, three children were referred to Salumbar District Hospital.

"Seventeen teams have been deployed in Lalpura and Ghata villages. Around 562 families live in this area," said Dr. Dinesh Rai Sapela, Additional District Collector.

Health teams are also conducting door-to-door screening, as well as collecting blood samples. These samples have been sent to RNT Medical College in Udaipur for testing.

“The exact cause behind the deaths is not yet known. It could be a viral infection or a seasonal disease, but confirmation will only come after test results,” said BCMO Dr Sintu Kumawat.

Meanwhile, Gayatri Rathore, Principal Secretary of the Medical and Health Department, stated that the Chief Medical and Health Officer of the Salumbar district has been instructed to form teams of health workers to ensure intensive screening of children exhibiting fever symptoms—not only in the affected villages but also throughout Salumbar and its surrounding regions, media reports said.

“Immediate treatment will be provided to any child showing symptoms. Critically ill children are to be referred without delay to district hospitals or medical college facilities,” Rathore said.

Authorities have also initiated preventive measures against possible mosquito-borne diseases, including anti-larval activities, source reduction, and fogging operations in the affected areas.

The Delhi government has announced the expansion of the newborn screening program to improve long-term health outcomes of children.

The move is aimed at achieving near-universal screening at government health facilities and outreach centers, according to an official statement.

From the earlier mandated 1.5 lakh children, the government has expanded the Mission ANMOL (Advanced Newborn Monitoring for Optimal Lifecare) to 2.5 lakh infants to ensure early detection of congenital disorders, PTI news agency quoted the officials as saying.

“The scale-up would enable early identification and management of metabolic, endocrine, functional, and visible congenital conditions, improving long-term health outcomes,” said Health Minister Pankaj Kumar Singh.

Notably, the program will focus on timely intervention and follow-up care for conditions such as

• congenital hypothyroidism,
• congenital heart defects,
• hearing impairment,
• retinopathy of prematurity.

What Is Mission ANMOL

Mission ANMOL was announced by the Delhi government on March 24, 2026, during the Delhi Budget session 2026–27.

Under the ANMOL scheme, 56 types of tests will be conducted using a single drop of blood from newborns, completely free of cost in both public and private hospitals.

Delhi Chief Minister, while presenting the Budget, said the scheme aims to ensure that such tests are not seen as a burden.

"Children are dear to all, they are ‘anmol' (translated as invaluable). To prevent genetic disorders, which are extremely expensive to treat, we are launching this scheme," the Chief Minister said.

Also read: Cancer Is The 10th Leading Cause Of Death In Indian Children: Study

How Will Mission ANMOL Work?

Mission ANMOL will adopt a technology-driven and integrated approach aligned with national guidelines to make comprehensive newborn screening a standard practice across Delhi's public health system.

To support implementation, the government has approved 148 positions under the program, including continuation of 73 existing staff and addition of 60 staff nurses and 15 optometrists, according to officials.

The nurses will assist in sample collection, especially for pre-term and critically ill infants, and help coordinate care and transport, while optometrists will support screening for retinopathy of prematurity, they said.

The initiative will also strengthen coordination among hospitals, laboratories, and program units to ensure all newborns are screened before discharge, with special emphasis on high-delivery-load hospitals and neonatal intensive care units.

Singh said the expanded program reflects the government's commitment to strengthening neonatal healthcare and ensuring that no child is left behind.

Also read: 41 million children aged 5-19 living with high BMI in India: Study

Why Newborn Screening Is Important?

Newborn screening can find the disease before the baby looks sick, and enable early treatment and possible cure for many genetic and metabolic diseases.

Genetic disorders can be life-threatening, impact growth, and even lead to physical and intellectual disabilities. The early screening tests detect hidden conditions early, preventing irreversible brain damage or physical disabilities.

Screening within 24 to 72 hours of birth can provide early access to medical care.

The screening test typically collects a blood sample from the heel of the baby by pricking, and the sample is sent to a laboratory for a biochemical test for screening of inherited conditions.

South Africa's National Department of Health has announced that it has received a first consignment of 37,920 doses of the groundbreaking, six-monthly HIV prevention injection, Lenacapavir.

Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) product that can help tackle the burden of HIV worldwide.

South Africa has the world's largest HIV-positive population of approximately 8 million people, with over 6 million currently on antiretroviral treatment.

“The department will, in the next few weeks, announce the official launch of this game changer where the phased implementation plan will be outlined,” said department spokesperson Foster Mohale, in a statement.

"Lenacapavir is preventive medicine, not a vaccine, considered one of the most exciting HIV prevention advances in years," Mohale said.

The Department noted that the medicine is expected to be sustain nearly half a million people in South Africa over the next two years, the statement said, adding that is will be officially rolled out in May.

Notably, the initial phase will target high-incidence districts and vulnerable groups.

What Is Lenacapavir?

Lenacapavir is a critical tool for reaching the Global AIDS Strategy goal of ending AIDS as a public health threat by 2030.

Lenacapavir injection as an additional PrEP option offers a highly effective, long-acting alternative to daily oral pills and other shorter-acting options.

With just two doses per year, lenacapavir is a transformative step forward in protecting people at risk of HIV -- particularly those who face challenges with daily adherence, stigma, or access to health care.

Marketed under the brand name Yeztugo, lenacapavir, developed by global pharma major Gilead Sciences, costs $28,218 per person per year.

However, it is being provided to South Africa through a $29-million USD grant from the Global Fund.

The shot was tested in two major studies involving high-risk groups: one with young women and teenage girls in South Africa and Uganda, and another with gay men and gender-diverse individuals in several countries. In both cases, the results were striking.

The women who received the shot had zero new HIV infections, compared to around 2% in those on daily pills. In the second study, the twice-yearly shot proved just as effective for men and gender non-conforming individuals.

“This really has the possibility of ending HIV transmission,” said Greg Millett of amfAR, The Foundation for AIDS Research.

Lenacapavir: How Does It Work?

Yeztugo is administered as two small injections in the abdomen, forming a medication "depot" that slowly releases the drug into the body over six months.

However, people must test negative for HIV before receiving it, as it doesn’t treat existing infections or prevent other sexually transmitted diseases.

Lenacapavir: Why Access Is A Challenge?

Despite its potential, concerns remain over who will actually benefit from lenacapavir.

In the US, only about 400,000 people currently use any form of PrEP — a small fraction of those who could benefit. And structural issues like cuts to public health funding, limited insurance access, and stigma pose significant barriers.

Globally, the challenge is even greater. While Gilead has struck deals with six generic drug makers, including four Indian, to provide low-cost versions of the shot for 120 low-income countries, critics argue that middle-income nations have been left out.

UNAIDS Executive Director Winnie Byanyima noted that at current prices, the shot “will change nothing” for many who need it.